Philippe Damier, Bertrand Degos, Giovanni Castelonovo, Mathieu Anheim, Isabelle Benatru, Nicolas Carrière, Olivier Colin, Luc Defebvre, Marie Deverdal, Alexandre Eusebio, Vanessa Ferrier, Caroline Giordana, Jean-Luc Houeto, Severine Le Dily, Marie Mongin, Claire Thiriez, Christine Tranchant, Denis Ravel, Jean-Christophe Corvol, Olivier Rascol, Yehezkel Ben Ari
BACKGROUND: Acting on the main target of dopaminergic cells, the striatal γ-aminobutyric acid (GABA)-ergic cells, might be a new way to treat persons with Parkinson's disease (PD). OBJECTIVE: The objective of this study was to assess the efficacy of bumetanide, an Na-K-Cl cotransporter (NKCC1) inhibitor, to improve motor symptoms in PD. METHODS: This was a 4-month double-blind, randomized, parallel-group, placebo-controlled trial of 1...
January 30, 2024: Movement Disorders: Official Journal of the Movement Disorder Society